0001193125-24-272655 Sample Contracts

BUSINESS SERVICES AGREEMENT
Business Services Agreement • December 9th, 2024 • Allovir, Inc. • Biological products, (no disgnostic substances) • Delaware

This Business Services Agreement (this “Agreement”) is effective July 1st, 2023 (the “Effective Date”), between Theia Therapeutics, Inc., a Delaware corporation (“Company”) and Samsara BioCapital, LLC, a Delaware limited liability company (“Samsara”).

View Source
ROYALTY AGREEMENT
Royalty Agreement • December 9th, 2024 • Allovir, Inc. • Biological products, (no disgnostic substances) • Delaware

This Royalty Agreement (this “Agreement”), is dated as of July 18, 2024 (the “Effective Date”), by and between Kalaris Therapeutics, Inc. (the “Company”) and Samsara BioCapital, L.P. (“Samsara”). The Company and Samsara may sometimes individually be referred to hereafter as a “Party” or collectively as the “Parties”.

View Source
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LICENSE AGREEMENT...
License Agreement • December 9th, 2024 • Allovir, Inc. • Biological products, (no disgnostic substances) • California

This License Agreement (“Agreement”) is made by and between Theia Therapeutics, Inc., a Delaware corporation having an address at 628 Middlefield Road, Palo Alto, CA 94301 (“LICENSEE”) and The Regents of the University of California, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation & Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UCSD”).

View Source
CONSULTING AGREEMENT
Consulting Agreement • December 9th, 2024 • Allovir, Inc. • Biological products, (no disgnostic substances) • California

This Consulting Agreement (this “Agreement”) is made and entered into effective as of July 1, 2021 (the “Effective Date”) by and between Theia Therapeutics, Inc., a Delaware corporation with its principal place of business at 628 Middlefield Road, Palo Alto, CA 94301 (the “Company”), and Napoleone Ferrara, M.D., an individual with an address at [***] (“Consultant”) (each herein referred to individually as a “Party,” or collectively as the “Parties”).

View Source